FIGURE 2.

SnPP administration increases plasma IL‐6 concentrations in healthy volunteers and subjects with CKD. Baseline plasma IL‐6 levels were significantly higher at baseline in the CKD versus the healthy volunteer group (<0.025). Despite the differing baseline IL‐6 concentrations, the fold increase over baseline values did not significantly differ for the CKD (7.25‐fold increase) versus the HV group (6.9‐fold increase). By 72 hr, plasma IL‐6 declines were apparent, but had still not returned to baseline levels. The values are presented after log base 10 transformation